Savara's Molgramostim Shows Promise in Autoimmune Pulmonary Alveolar Proteinosis
Key Insights
Savara Inc. announced an encore presentation of Phase 3 IMPALA-2 trial results for Molgramostim at the British Thoracic Society Winter Meeting 2024.
The IMPALA-2 trial demonstrated that inhaled Molgramostim improves pulmonary gas exchange in patients with autoimmune Pulmonary Alveolar Proteinosis (search) (aPAP (search)).
Dr. Cormac McCarthy presented data showing Molgramostim also enhances respiratory health-related quality of life in aPAP (search) patients.
Savara Inc. (Nasdaq: SVRA) presented results from its Phase 3 IMPALA-2 trial of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (search) (aPAP (search)) at the British Thoracic Society (BTS) Winter Meeting in London. The data, presented by Dr. Cormac McCarthy on November 29, 2024, highlight molgramostim's potential to improve pulmonary gas exchange and respiratory health-related quality of life in aPAP patients.
IMPALA-2 Trial Results
The IMPALA-2 trial evaluated the efficacy and safety of inhaled molgramostim in patients with aPAP (search), a rare lung disease characterized by surfactant accumulation in the alveoli. The study met its primary endpoints, demonstrating statistically significant improvements in pulmonary gas exchange and key secondary endpoints related to respiratory function and quality of life.
Mechanism of Action and Clinical Significance
Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). In aPAP (search), antibodies neutralize GM-CSF, impairing alveolar macrophage function and surfactant clearance. Molgramostim aims to restore macrophage function, facilitating surfactant clearance and improving gas exchange. The clinical significance lies in addressing the unmet need for effective therapies in aPAP, where current treatment options are limited and can be invasive.
Presentation Details
Dr. McCarthy's presentation, titled "Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with Autoimmune Pulmonary Alveolar Proteinosis (search) (aPAP (search)): Results from IMPALA-2," took place during the "The Famous Five" session at the BTS Winter Meeting. The presentation slides are available on the Articles & Publications page of Savara's corporate website.
About aPAP
Autoimmune PAP is a rare condition where surfactant builds up in the lung's air sacs, impairing gas exchange and causing shortness of breath, cough, and fatigue. Long-term complications include lung fibrosis and the potential need for lung transplantation. Savara is focused on addressing this unmet medical need with molgramostim.